Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 57.67 0.9 (1.59%) Market Cap: 5.35 Bil Enterprise Value: 4.54 Bil PE Ratio: 0 PB Ratio: 5.60 GF Score: 39/100

Crinetics Pharmaceuticals Inc To Discuss Results From MAD Cohorts Of The Phase 1 Trial Of CRN04777 Corporate Call Transcript

Mar 30, 2022 / 08:30PM GMT
Release Date Price: $19 (-3.41%)
Operator

Greetings, and welcome to Crinetics Pharmaceuticals conference call. (Operator Instructions). As a reminder, this conference is being recorded.

I would now like to turn this conference over to your host, Mr. Thomas Galassi with LifeSci Advisors. Thank you, sir. You may begin.

Thomas Galassi
LifeSci Advisors, LLC - MD of Investor Communications

Thank you, operator, and thank you all for participating in today's conference call.

Before we start, I would like to point out that there is a slide deck that will accompany today's presentation. This slide deck can be viewed using the webcast link provided on the Investors page of the Crinetics Pharmaceuticals website. Also posted on this web page is a news release issued earlier today, announcing top line data for the multiple ascending dose portion of the Phase I study evaluating CRN04777, which is the topic of today's call.

However, before we get to discussion of the Phase I results, I'd like to remind all listening and some of the information contained in the news release and on this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot